TrialBritish journal of cancer2018

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.

Philip E Lammers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.